About Melt Pharmaceuticals
Melt Pharmaceuticals is a company based in United States founded in 2018 was acquired by Harrow in September 2025. Melt Pharmaceuticals has raised $77.29 million across 3 funding rounds from investors including Harrow. Melt Pharmaceuticals offers products and services including MELT-300 and Combination Drug Formulations.
- Headquarter United States
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Melt Pharmaceuticals, Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Melt Pharmaceuticals
Melt Pharmaceuticals offers a comprehensive portfolio of products and services, including MELT-300 and Combination Drug Formulations.
A sublingual tablet is developed for needle- and opioid-free procedural sedation and analgesia in short-duration medical procedures
Non-intravenous and non-opioid sedation formulations are created to address sedation needs in outpatient settings
Funding Insights of Melt Pharmaceuticals
Melt Pharmaceuticals has successfully raised a total of $77.29M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $24 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Melt Pharmaceuticals
Melt Pharmaceuticals has secured backing from 1 investor. Prominent investors backing the company include Harrow.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Ophthalmic products marketing services are provided by Harrow.
|
Locked | Locked | Locked |
Investor details for Melt Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Melt Pharmaceuticals
Investment portfolio details for Melt Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Melt Pharmaceuticals
Detailed financials for Melt Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Melt Pharmaceuticals Comparisons
Peer comparison for Melt Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Melt Pharmaceuticals
Detailed competitors of Melt Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Melt Pharmaceuticals
Complete news archive for Melt Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Melt Pharmaceuticals
Melt Pharmaceuticals was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Melt Pharmaceuticals is headquartered in United States.
Melt Pharmaceuticals is a funded company, having raised a total of $77.29M across 3 funding rounds to date.
Melt Pharmaceuticals was founded in 2018 and is headquartered in the United States. Operations are centered in the pharmaceutical sector, though specific services and products remain undisclosed in available records. The companys domain, meltpharma.com, serves as its online presence. Limited public data exists on detailed activities, with focus inferred on drug development or related innovations typical to the industry.
Melt Pharmaceuticals offers MELT-300 and Combination Drug Formulations.
Melt Pharmaceuticals has 1 investor. Key investors include Harrow.